Anavex Life Sciences Corp. $AVXL Shares Acquired by LPL Financial LLC

Key Points

• LPL Financial LLC significantly increased its stake in Anavex Life Sciences by 482.1% during the first quarter, owning a total of 546,626 shares valued at approximately $4.69 million.
• Other institutional investors also raised their holdings in Anavex Life Sciences, with notable increases from Invesco Ltd. at 2,419.8% and Envestnet Asset Management Inc. at 54.2% in the previous quarter.
• Anavex Life Sciences' recent earnings report showed a loss of ($0.16) EPS, which missed analysts' expectations of ($0.13) EPS for the quarter.

LPL Financial LLC increased its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 482.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 546,626 shares of the biotechnology company's stock after buying an additional 452,723 shares during the period. LPL Financial LLC owned about 0.64% of Anavex Life Sciences worth $4,690,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,708 shares during the last quarter. SeaCrest Wealth Management LLC lifted its holdings in Anavex Life Sciences by 15.0% during the first quarter. SeaCrest Wealth Management LLC now owns 17,600 shares of the biotechnology company's stock valued at $151,000 after purchasing an additional 2,300 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Anavex Life Sciences by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 223,131 shares of the biotechnology company's stock worth $1,914,000 after purchasing an additional 2,882 shares during the last quarter. Vermillion Wealth Management Inc. acquired a new stake in Anavex Life Sciences in the 4th quarter valued at about $34,000. Finally, Ameriprise Financial Inc. raised its holdings in Anavex Life Sciences by 5.1% in the 4th quarter. Ameriprise Financial Inc. now owns 66,810 shares of the biotechnology company's stock valued at $718,000 after acquiring an additional 3,243 shares during the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Trading Down 2.4%

AVXL traded down $0.24 on Monday, hitting $9.71. The company had a trading volume of 319,117 shares, compared to its average volume of 1,126,099. The firm has a market cap of $834.25 million, a P/E ratio of -17.04 and a beta of 0.80. Anavex Life Sciences Corp. has a 1 year low of $4.93 and a 1 year high of $14.44. The company's fifty day moving average price is $10.34 and its 200 day moving average price is $9.20.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). On average, analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, August 13th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.